Baron Financials ETF on Ascendis Pharma
Thesis
Baird added Ascendis Pharma as part of an increase in exposure to commercial-stage therapeutics companies with promising growth potential. Ascendis has developed a proprietary drug platform called TransCon. The platform has already produced three drugs targeting rare endocrine diseases, providing the basis for the fund's interest.
“Ascendis Pharma has a proprietary drug platform called TransCon that has led to three drugs for rare endocrine diseases”